Literature DB >> 7779027

Acute simultaneous bilateral vestibulocochlear impairment in neuro-Behçet's disease: a case report.

I Tsunoda1, H Kanno, M Watanabe, S Shimoji, K Hirayama, H Sumita, T Yamamoto.   

Abstract

The central nervous system (CNS) is often a preferential target of Behçet's disease and diverse neurological manifestations have been described. Isolated hearing impairment or disequilibrium is also known to occur, but the simultaneous bilateral impairment of both vestibular and cochlear functions has been only rarely documented in Behçet's disease. A 52-year-old Japanese woman with neuro-Behçet's disease had meningoencephalitis, a profound thrombocytopenia, and bilateral vestibulocochlear impairment during the acute exacerbation. Although the CNS involvement was apparent, the clinical history and neuro-otological findings pointed to bilateral inner ear involvement rather than the brainstem or the 8th nerve lesions. She has made an excellent clinical response to pulse-dose methylprednisolone therapy with improvement in her neurological symptoms and in arresting the acute deterioration of hearing loss, but repeated audiograms failed to maintain the improvement with a modest dose of oral prednisolone. Since the bilateral vestibulocochleopathy can be as incapacitating as oculopathy in Behçet's disease, an early detection and prompt instillation of adequate corticosteroid therapy may be mandatory, although not curative.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7779027     DOI: 10.1016/s0385-8146(12)80088-5

Source DB:  PubMed          Journal:  Auris Nasus Larynx        ISSN: 0385-8146            Impact factor:   1.863


  2 in total

1.  High dose intravenous steroid therapy for severe posterior segment uveitis in Behçet's disease.

Authors:  E Toker; H Kazokoğlu; N Acar
Journal:  Br J Ophthalmol       Date:  2002-05       Impact factor: 4.638

Review 2.  Current concepts in acute vestibular syndrome and video-oculography.

Authors:  Georgios Mantokoudis; Jorge Otero-Millan; Daniel R Gold
Journal:  Curr Opin Neurol       Date:  2022-02-01       Impact factor: 5.710

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.